Major Depressive Disorder

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

Phase 4 trial shows esketamine provides significant symptom relief in patients with treatment-resistant depression within 24 hours of the first dose.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

Jain discussed Rejoyn, the FDA-approved digital therapeutic app that enhances major depressive disorder treatment with engaging brain training and mindfulness exercises.

Alto Neuroscience developed an EEG biomarker that predicts placebo response in MDD trials, potentially improving drug effect detection and reducing trial variability.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

A study links daily discrimination to greater depression and anxiety rates, with marginalized groups facing greater mental health risks across the US.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

A new study found antidepressant use drops by nearly 50% during pregnancy, but without increased psychotherapy, raising concerns about untreated depression risks.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.